1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.

1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.

1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.

1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.

Hypertension

This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.

Rostafuroxin

COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole- 5-methanol monopotassium salt.

Losartan

Cvie Therapeutics Limited

Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

Antihypertensive Effect of Different Doses of ROSTAFUROXIN in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile.

Automated sitting and standing SBP and DBP will be recorded by physician at baseline (two visits) and at week 2, 5 and 9 of treatement.
sitting: after the patient has rested for at least 10 minutes in a quiet room. There are five consecutive sitting BP readings with a 30 to 60 seconds interval between the readings; the mean of the last three sitting BP will be used.

Diastolic blood pressure measurements will be performed at the same times of the systolic blood pressure measurements, as described above

Ambulatory Blood Pressure Monitoring (ABPM)will be performed throuhgout 24 hours at baseline and at week 9 of treatement. Readings will be Centralized. The Core Laboratory will be in charge for data interpretation

All the Adverse Events will be recorded and followed-up till their resolution. Number of Adverse Events in each group treatment will be computed, including single event frequencies and number of patients with adverse events. AEs will be collected on spontaneous reporting by patients and a number of standard safety procedure: i.e. recording of ECGs, standard blood chemistry and haematology, performed before, during and at the end of the treatment period.

Windtree Therapeutics

Structurally normal heart, no bundle branch block

Mild symptoms, bundle brunch block or hemi-block on resting surface electrocardiogram, normal cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction as relaxation deficit (type I), none or mild global left ventricular systolic dysfunction

Overtly symptomatic, enlarged cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction, global systolic dysfunction, ventricular tachycardia, atrio-ventricular block (any degree)

Chagas Cardiomyopathy

Cardiac Arrhythmia

Stroke

Left Ventricular Function Systolic Dysfunction

Cardiac Death

University of Texas at Houston

Hospital Universitário Pedro Ernesto

Universidade Gama Filho

Instituto Nacional de Cardiologia

The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort

Prognostic Value of the Spectral Turbulence Analysis of the Signal-averaged Electrocardiogram in Chagas Heart Disease

Defined as intractable heart failure, arrhythmic, coronary occlusion, or sudden death.
Assessment twice an year by active and direct contact to subjects or relatives and review of medical records.

New onset ventricular tachycardia defined as symptomatic (palpitations, dizziness or syncope), >=3 consecutive beats, bundle branch block configuration, ventricular rate >100bpm, atrial-ventricular dissociation.
Assessed with 24h-ambulatory electrocardiogram monitoring requested at discretion of non-investigational primary evaluation and confirmed by review of medical records.

Evidence of clinically definite stroke (focal neurological deficits persisting for more than 24 hours) confirmed or not by non-investigational CT.
Assessment twice an year by active and direct contact to patents or relatives and review of medical records.

Irregular non-sinus interbeat interval, lasting more that 24h, confirmed by either non-investigational 24h ambulatory electrocardiogram monitoring or resting 12-lead surface electrocardiogram two to four times a year.
Assessment by review of medical records.

Non-investigational M-mode/2-D echocardiographic evaluation at the discretion of primary care assistance.
Assessment by review of medical records.

Paulo Roberto Benchimol Barbosa

Head Researcher

Rio de Janeiro State University

The University of Texas Health Science Center, Houston

Instituto Nacional de Cardiologia de Laranjeiras

Essential Hypertension

Portiuncula Hospital

James Connolly memorial Hospital

Clinical research centre, Beaumont Hospital

Unità Operativa di Nefrologia e Dialisi, Ospedale "S. Maria della Scaletta"

Ospedale "Santa Maria"

Divisione di Cardiologia e UTIC Ospedale "Marianna Giannuzzi"

Reparto di Emodialisi, Ospedale dell'Angelo

U.O. di Nefrologia e Dialisi, Ospedale San Donato

U.O Nefrologia, Dialisi e Ipertensione, Policlinico S. Orsola-Malpighi

Cattedra di Medicina Interna, U.O. Malattie Cardiovascolari, Policlinico Universitario Campus Germaneto

Centro per l'Ipertensione, Ospedale F. Veneziale

U.O.C. di Medicina Interna Universitaria 1, Ospedale San Salvatore

U.O. Nefrologia e Dialisi, Spedali Riuniti

Divisione di Nefrologia, Dialisi e Ipertensione Ospedale San Raffaele

U.O. Nefrologia e Dialisi, Università degli Studi di Milano Azienda Ospedaliera San Paolo

Clinica Medica 3, Dipartimento di Scienze Mediche e Chirurgiche

Reparto Emodialisi, Clinica "Domus Nova"

Nefrologia e Dialisi, Ospedale Infermi

Centro per l'Ipertensione, A.S.L. n° 1

U.O. Nefrologia e Dialisi Presidio Ospedaliero "Giuseppe Mazzini"

Centro Ipertensione Arteriosa, SCU Medicina Interna 4, A.O.U. San Giovanni Battista

Institute of Cardiology, Department of Coronary Disease, Jagiellonian University

Institute of Cardiology, I Department of Cardiology and Hypertension, Jagiellonian University

Internal Medicine and Gerontology, Jagiellonian University Medical College

Institute of Cardiology, Department of Hypertension, University of Medical Sciences

The Cardinal Stefan Wyszynski Institute of Cardiology - Arterial Hypertension Clinic

Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations

Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile

Automated sitting and standing SBP and DBP will be recorded by physician at baseline (two visits) and at week 2, 5 and 9 of treatement.
sitting: after the patient has rested for at least 10 minutes in a quiet room. There are five consecutive sitting BP readings with a 30 to 60 seconds interval between the readings; the mean of the last three sitting BP will be used.
The standing BP is measured twice immediately after the patient assumed the standing position.

Diastolic blood pressure measurements will be performed at the same times of the systolic blood pressure measurements, as described above.

Ambulatory Blood Pressure Monitoring (ABPM)will be performed throuhgout 24 hours at baseline and at week 9 of treatement. Readings will be Centralized. The Core Laboratory will be in charge for data interpretation.

cardiomegaly/بوتاسيوم

Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort

Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم